DISCONTINUATION RATES ACROSS THREE PHASE III TRIALS OF THE AMPA RECEPTOR ANTAGONIST PERAMPANEL AS AN ADJUNCTIVE TREATMENT FOR REFRACTORY PARTIAL SEIZURES

被引：0
|
作者：
Yang, H. [1 ]
Squillacote, D. [2 ]
Zhu, J. [1 ]
Laurenza, A. [1 ]
Satlin, A. [1 ]
Kramer, L. D. [1 ]
机构：
[1] Eisai Neurosci Prod Creat Unit, Woodcliff Lake, NJ USA
[2] Eisai Global Med Affairs, Woodcliff Lake, NJ USA
来源：
EPILEPSIA | 2013年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [31] ADJUNCTIVE ONCE-DAILY PERAMPANEL REDUCES SEIZURE FREQUENCY AND IMPROVES RESPONDER RATES IN PATIENTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURES, IRRESPECTIVE OF AGE AT EPILEPSY DIAGNOSIS: A POOLED ANALYSIS OF THREE PHASE III TRIALS
    Squillacote, D.
    Yang, H.
    Kumar, D.
    Laurenza, A.
    EPILEPSIA, 2013, 54 : 167 - 167
  • [32] Extrapolation of Adjunctive Efficacy and Safety Data from Phase III Partial Epilepsy Trials to Evaluate Perampanel as Monotherapy
    Mintzer, Scott
    French, Jacqueline
    Williams, Betsy
    Patten, Anna
    Laurenza, Antonio
    NEUROLOGY, 2018, 90
  • [33] ADJUNCTIVE PERAMPANEL IN PATIENTS WITH DRUG-RESISTANT PARTIAL SEIZURES WITH AND WITHOUT CONCURRENT VNS THERAPY IN PHASE III STUDIES
    Klein, P.
    Laurenza, A.
    Williams, B.
    Patten, A.
    EPILEPSIA, 2017, 58 : S105 - S105
  • [34] Perampanel, a selective, noncompetitive ℵ-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307
    Krauss, Gregory L.
    Perucca, Emilio
    Ben-Menachem, Elinor
    Kwan, Patrick
    Shih, Jerry J.
    Squillacote, David
    Yang, Haichen
    Gee, Michelle
    Zhu, Jin
    Laurenza, Antonio
    EPILEPSIA, 2013, 54 (01) : 126 - 134
  • [35] LONG-TERM SEIZURE OUTCOMES WITH PERAMPANEL IN REFRACTORY PARTIAL-ONSET SEIZURES AND SECONDARILY GENERALISED PARTIAL SEIZURES: 10 MONTHS ADDITIONAL DATA FROM EXTENSION STUDY 307 FOLLOWING THREE PHASE III CLINICAL TRIALS
    Ben-Menachem, Elinor
    Krauss, Gregory
    Bagul, Makarand
    Zhu, Jin
    Gee, Michelle
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (10):
  • [36] Psychiatric and cognitive adverse events: A pooled analysis of three phase III trials of adjunctive eslicarbazepine acetate for partial-onset seizures
    Andermann, Eva
    Biton, Victor
    Benbadis, Selim R.
    Shneker, Bassel
    Shah, Aashit K.
    Carreno, Mar
    Trinka, Eugen
    Ben-Menachem, Elinor
    Biraben, Arnaud
    Rocha, Francisco
    Gama, Helena
    Cheng, Hailong
    Blum, David
    EPILEPSY & BEHAVIOR, 2018, 82 : 119 - 127
  • [37] EFFICACY AND SAFETY OF PERAMPANEL AS ADJUNCTIVE THERAPY IN ADOLESCENTS WITH REFRACTORY PARTIAL-ONSET SEIZURES: ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY
    Villanueva, V.
    Rozentals, G.
    Yang, H.
    Squillacote, D.
    Zhu, J.
    Laurenza, A.
    EPILEPSIA, 2011, 52 : 242 - 242
  • [38] Adjunctive Perampanel 4 mg/day for Partial-Onset Seizures (POS): Time to Seizure Onset in Pivotal Phase III Studies
    Salah, A.
    Patten, A.
    Malhotra, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 290 - 291
  • [39] ADJUNCTIVE PERAMPANEL DOES NOT INCREASE THE RISK OF CARDIAC ADVERSE EVENTS COMPARED WITH PLACEBO: A POOLED ANALYSIS OF THREE PHASE III TRIALS
    Laurenza, A.
    Yang, H.
    Squillacote, D.
    Kumar, D.
    Satlin, A.
    Kramer, L. D.
    EPILEPSIA, 2013, 54 : 70 - 70
  • [40] Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials
    Slater, Jeremy
    Chung, Steve
    Huynh, Lynn
    Duh, Mei Sheng
    Gorin, Brian
    McMicken, Carolyn
    Ziemann, Adam
    Isojarvi, Jouko
    EPILEPSY RESEARCH, 2018, 143 : 120 - 129
12345